We compared several siRNA transfection reagents by evaluating the expression inhibition of the epithelial-glycoprotein EpCAM on SKOV-3 tumor cells.

10,000 cells were seeded in a 96 well plate and transfected with 3 pmol siRNA (which results in a final concentration of siRNA of 15nM).

Click here to read more about this experiment.

Last November, van der Gun et al. published an article high-lighting the unique advantages of the SAINT protein delivery reagent: SAINT-PhD.

1. Delivery of the protein is independent of the
   size and charge.
2. Delivery efficiency is high: up to 98% of
   adherent cells, up to 83% of suspension
   cells and up to 70% of primary cells are
   shown to have taken up the protein
   transported by SAINT-PhD into the cells.
3. Intracellular delivery of proteins by SAINT-PhD
   is not significantly affected by the presence
   of serum. This is a major advantage,
   because most competitors (e.g. Bioporter)
   are not able to deliver proteins into cells
   in the presence of serum. Furthermore, the
   presence of serum is self-evident in in vivo
   protein delivery experiments and applications.
4. The delivered protein can exert its function both
   in the cytoplasm and in the nucleus. For
   example, a methyltransferase enzyme was
   delivered using SAINT-PhD resulting in
   DNA methylation leading to a decrease in
   expression.
5. SAINT-PhD does not affect cell viability.

B.T.F. van der Gun et al., Serum insensitive, intranuclear protein delivery by the multipurpose cationic lipid SAINT-2, J. Control. Release. (2007), doi:10.1016/j.jconrel.2007.08.014

SAINT-PhD protein delivery reagent.
Proudly we announce the availability of the improved SAINT-PhD protein delivery
reagent for the non-cytotoxic delivery of biologically active cargo molecules,
such as proteins, antibodies or small peptides, directly into living cells.

This unique reagent will be an effective tool for pathway research and analysis, target validation
and protein or peptide library screening. The novel SAINT molecules are put into a new formulation
optimized for a fast and easy method to study protein function on a cellular level directly. This approach
will avoid the problems of DNA transfections such as promoter interference and unpredictable levels of
transfection in particular cells.

Click here to read more about these remarkable features.

The ability of embryonic stem cells to differentiate into specific cell types implies huge potential for therapeutic use in cell and gene therapy and for the efficient generation of transgenic and knock-out animals.

One of the bottlenecks has always been the effective genetic manipulation of ES cells. We have developed a robust procedure to deliver DNA into ES cells. The method is superior to e.g. electroporation, which suffers from very high mortality rates (up to 90%), very low viability of the cells after the procedure and large quantities of DNA required.

Click here to read more about DNA Transfection of Embryonic Stem cells.